{"id":"W2602169105","doi":"10.1182/blood-2016-11-750158","title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary","funders":"National Cancer Institute; Karyopharm Therapeutics","keywords":"Medicine; Internal medicine; Adverse effect; Myeloid leukemia; Population; Hazard ratio; Toxicity; Phases of clinical research; Refractory (planetary science); Oncology; Cancer; Gastroenterology; Confidence interval; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001425297,0.0001955061,0.0007992121,0.0001784597,0.00009500271,0.00004120062,0.0005256076,0.0002732894,0.00009907626],"category_scores_gemma":[0.002381551,0.0001641111,0.0002733211,0.0001281015,0.0003254451,0.0001187245,0.0002699243,0.0006390015,0.00009474371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002224767,"about_ca_system_score_gemma":0.001215711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001516883,"about_ca_topic_score_gemma":0.00003852724,"domain_scores_codex":[0.9974648,0.0001428335,0.0009638456,0.0004513329,0.0005249368,0.0004521951],"domain_scores_gemma":[0.9975515,0.0002195717,0.0003648613,0.001400174,0.0001669659,0.000296914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2794412,0.06876911,0.04456968,0.0005033454,0.002912891,0.007384053,0.0009344252,0.00000253352,0.3798719,0.0002314401,0.01600694,0.1993725],"study_design_scores_gemma":[0.8983233,0.01313787,0.01122584,0.0002781577,0.0008828503,0.0001845627,0.00007000392,0.0004508043,0.06340632,0.00008080187,0.01164142,0.0003180669],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931136,0.0001087453,0.00003763105,0.001223437,0.000337803,0.001072359,0.00003144922,0.00003792227,0.004037098],"genre_scores_gemma":[0.9946389,0.000306791,0.002191046,0.0001971571,0.0009859144,0.00004969451,0.00002870054,0.00004041399,0.001561342],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6188821,"threshold_uncertainty_score":0.6692255,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1026217167358261,"score_gpt":0.4179450152060915,"score_spread":0.3153232984702654,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}